Chimeric antigen receptor-engineered T cells and its clinical application
10.3760/cma.j.issn.1009-9921.2016.10.017
- VernacularTitle:嵌合抗原受体T细胞技术及其临床应用
- Author:
Yue SHI
;
Xiaolong LIAO
- Publication Type:Journal Article
- Keywords:
Chimeric antigen receptor T-cell;
Lymphoma;
Leukemia
- From:
Journal of Leukemia & Lymphoma
2016;25(10):629-632
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T-cell (CAR-T) technology is based on genetic modification technology to express T-cell expression tumor specific chimeric antigen receptor bind tumor antigen in an antigen-dependent anti-MCH way. Single chain antibody fragment (scFv) of tumor-associated antigen (TAA) combines with up-stream activating sequence of T-cell in vitro. The forming recombinant plasmid transfects the purified and large scale proliferating T-cell in vitro by transfection technique. This process starts and activates specific killing reaction of tumor. The clinical application of cell therapy shows high efficiency and good anti-tumor effect in treatment of malignant neoplasm, such as leukemia, lymphoma, melanoma, which made CAR-T become the mainstream method of cell therapy.
